Clinical study of Silibinin Capsules combined with tenofovir amibufenamide in treatment of chronic hepatitis B
Objective To investigate the clinical efficacy of Silibinin Capsules combined with tenofovir amibufenamide in treatment of chronic hepatitis B.Methods A total of 96 patients with chronic hepatitis B treated in Rugao People's Hospital from August 2021 to June 2024 were selected and divided into control group and treatment group according to random number table method,with 48 patients in each group.Patients in control group received Tenofovir Amibufenamide Tablets with food,1 tablet/time,once daily.Patients in treatment group were po administered with Silibinin Capsules on basis of the control group,3 capsules/time,3 times daily.Both groups were treated for 12 weeks.The clinical efficacy and symptom remission time of two groups were observed,and the changes of liver function index,QOL-HBV score,NLR,HBV DNA,IL-17,SOD,MDA,GP73,and MMP-2 were compared before and after treatment.Results After treatment,the total effective rate of treatment group was 93.75%,which was significantly higher than that of control group(79.17%,P<0.05).The relief time of fatigue,anorexia,nausea and hepatic discomfort in treatment group was significantly shorter than that in control group(P<0.05).After treatment,serum ALT,TBIL,and AST levels in two groups were lower than those before treatment(P<0.05).After treatment,ALT,TBIL and AST levels in treatment group were lower than those in control group(P<0.05).After treatment,QOL-HBV scores were significantly increased and serum HBV DNA levels were significantly decreased in both groups(P<0.05).After treatment,QOL-HBV score and serum HBV DNA level in treatment group were better than those in control group(P<0.05).After treatment,the levels of NLR,IL-17,MDA,GP73,and MMP-2 in both groups were lower than those before treatment,and the level of SOD in serum was significantly increased(P<0.05).After treatment,the levels of NLR,IL-17,SOD,MDA,GP73,and MMP-2 in treatment group were better than those in control group(P<0.05).Conclusion In treatment of chronic hepatitis B with Silibinin Capsules combined with tenofovir amibufenamide,patients have good tolerance,and it can effectively accelerate the degree of virus infection and symptoms of patients,promote the recovery of liver function and improve the life quality,which is worthy of clinical application.
万方数据
